Cargando…
New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran
Dyslipidaemias and in particular elevated plasma low-density lipoprotein cholesterol (LDL-C) levels are major risk factors for atherosclerotic cardiovascular disease (ASCVD). Indeed, the more LDL-C is reduced the larger will be the ASCVD risk reduction. Although statins represent the first-line inte...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503511/ https://www.ncbi.nlm.nih.gov/pubmed/34650356 http://dx.doi.org/10.1093/eurheartj/suab090 |
_version_ | 1784581138905300992 |
---|---|
author | Ruscica, Massimiliano Sirtori, Cesare Riccardo Ferri, Nicola Corsini, Alberto |
author_facet | Ruscica, Massimiliano Sirtori, Cesare Riccardo Ferri, Nicola Corsini, Alberto |
author_sort | Ruscica, Massimiliano |
collection | PubMed |
description | Dyslipidaemias and in particular elevated plasma low-density lipoprotein cholesterol (LDL-C) levels are major risk factors for atherosclerotic cardiovascular disease (ASCVD). Indeed, the more LDL-C is reduced the larger will be the ASCVD risk reduction. Although statins represent the first-line intervention to reduce the atherosclerotic burden driven by raised levels of LDL-C, adherence is not optimal and most patients do not follow guidelines and recommended doses. Thus, to achieve optimal LDL-C goals, especially in very high-risk patients, there is a need for new and safe agents, more tolerable than statins with low risk of myalgia. Thus, the present review will address the most recent clinical trials with bempedoic acid and inclisiran. Bempedoic acid is an oral drug acting at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and not associated with muscular side effects. Inclisiran, the first-in-class small interfering RNA-based approach, has the ability to effectively reduce LDL-C by inhibiting the hepatic synthesis of proprotein convertase subtilisin/kexin type 9, with the advantage of requiring subcutaneous of a single dose on Day 1, Day 90, and every 6 months thereafter. |
format | Online Article Text |
id | pubmed-8503511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-85035112021-10-13 New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran Ruscica, Massimiliano Sirtori, Cesare Riccardo Ferri, Nicola Corsini, Alberto Eur Heart J Suppl Articles Dyslipidaemias and in particular elevated plasma low-density lipoprotein cholesterol (LDL-C) levels are major risk factors for atherosclerotic cardiovascular disease (ASCVD). Indeed, the more LDL-C is reduced the larger will be the ASCVD risk reduction. Although statins represent the first-line intervention to reduce the atherosclerotic burden driven by raised levels of LDL-C, adherence is not optimal and most patients do not follow guidelines and recommended doses. Thus, to achieve optimal LDL-C goals, especially in very high-risk patients, there is a need for new and safe agents, more tolerable than statins with low risk of myalgia. Thus, the present review will address the most recent clinical trials with bempedoic acid and inclisiran. Bempedoic acid is an oral drug acting at a biochemical step preceding hydroxymethylglutaryl-CoA reductase and not associated with muscular side effects. Inclisiran, the first-in-class small interfering RNA-based approach, has the ability to effectively reduce LDL-C by inhibiting the hepatic synthesis of proprotein convertase subtilisin/kexin type 9, with the advantage of requiring subcutaneous of a single dose on Day 1, Day 90, and every 6 months thereafter. Oxford University Press 2021-10-08 /pmc/articles/PMC8503511/ /pubmed/34650356 http://dx.doi.org/10.1093/eurheartj/suab090 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2021. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Ruscica, Massimiliano Sirtori, Cesare Riccardo Ferri, Nicola Corsini, Alberto New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
title | New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
title_full | New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
title_fullStr | New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
title_full_unstemmed | New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
title_short | New players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
title_sort | new players in the treatment of hypercholesterolaemia: focus on bempedoic acid and inclisiran |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503511/ https://www.ncbi.nlm.nih.gov/pubmed/34650356 http://dx.doi.org/10.1093/eurheartj/suab090 |
work_keys_str_mv | AT ruscicamassimiliano newplayersinthetreatmentofhypercholesterolaemiafocusonbempedoicacidandinclisiran AT sirtoricesarericcardo newplayersinthetreatmentofhypercholesterolaemiafocusonbempedoicacidandinclisiran AT ferrinicola newplayersinthetreatmentofhypercholesterolaemiafocusonbempedoicacidandinclisiran AT corsinialberto newplayersinthetreatmentofhypercholesterolaemiafocusonbempedoicacidandinclisiran |